Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
McKesson
McKinsey
AstraZeneca
Moodys

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

CREON Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Creon patents expire, and when can generic versions of Creon launch?

Creon is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug.

This drug has forty-nine patent family members in twenty-three countries.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

US ANDA Litigation and Generic Entry Outlook for Creon

  Start Trial

Creon was eligible for patent challenges on April 30th, 2013.

Annual sales in 2017 were $1.7bn, indicating a strong incentive for generic entry.

US Patents and Regulatory Information for CREON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-002 Apr 30, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-003 Apr 30, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-001 Apr 30, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-004 Jul 12, 2011 RX Yes No   Start Trial   Start Trial Y   Start Trial
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-004 Jul 12, 2011 RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-005 Mar 14, 2013 RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-005 Mar 14, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
AstraZeneca
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.